RayKnowChina Research Map
Shortlist0

Sichuan University (West China)

四川大学华西

ChengduUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
1.9%Leads about 1 in 52 of China's research papers on NPC

Led 46 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
2
Research papers it led
46
Trials it led
6
Share of China's trials
1.0%
Share of the world's papers
1.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueInduction / concurrent chemotherapy

Hospitals counted here

  1. West China Hospital44
  2. West China Second University Hospital Counted in the group total2
  3. West China Hospital of Stomatology1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.2025Oral oncologyRCT
  2. Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors.2025Cancer immunology, immunotherapy : CIIRCTFree full text
  3. Tumor Treatment Response-Guided Adaptive Dose De-escalation/Escalation Strategy for Concurrent Chemoradiation Therapy of Nasopharyngeal Carcinoma.2026International journal of radiation oncology, biology, physics
  4. Fertility, gonadal and sexual function in survivors of nasopharyngeal carcinoma patients.2025BMC cancerFree full text
  5. Dynamic joint prediction model of severe radiation-induced oral mucositis among nasopharyngeal carcinoma: a prospective longitudinal study.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Trials on ClinicalTrials.gov6
  1. Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck TumorsRecruitingNCT07625423Lead sponsorPhase 1Start 2026-03
  2. A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)RecruitingNCT07035626Lead sponsorPhase 1/Phase 2Start 2025-06
  3. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  4. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaRecruitingNCT07328854Study sitePhase 3Start 2025-11
  5. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Study sitePhase 2Start 2025-04
  6. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
2.5%Leads about 1 in 41 of China's research papers on ESCC

Led 72 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
6
Research papers it led
72
Trials it led
13
Share of China's trials
2.3%
Share of the world's papers
1.7%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025
ThemesNeoadjuvant & combined treatmentSurgeryImaging & AI

Hospitals counted here

  1. West China Hospital71
  2. West China Hospital of Stomatology Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effect of an artificial intelligence-assisted system on endoscopic diagnosis of superficial oesophageal squamous cell carcinoma and precancerous lesions: a multicentre, tandem, double-blind, randomised controlled trial.2024The lancet. Gastroenterology & hepatologyRCT
  2. Targeting TFAP2β condensation suppresses the development of esophageal squamous cell carcinoma.2026Cell
  3. Comprehensive landscape of resistance mechanisms for neoadjuvant therapy in esophageal squamous cell carcinoma by single-cell transcriptomics.2023Signal transduction and targeted therapyFree full text
  4. Identifying a confused cell identity for esophageal squamous cell carcinoma.2022Signal transduction and targeted therapyFree full text
  5. Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma.2022GutFree full text
Trials on ClinicalTrials.gov6
  1. Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCCRecruitingNCT07519486Lead sponsorPhase 2Start 2026-04
  2. Oncolytic Virus in Esophageal Squamous Cell CarcinomaRecruitingNCT07061704Lead sponsorPhase 1/Phase 2Start 2025-08
  3. A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06753747Lead sponsorPhase 1/Phase 2Start 2025-09
  4. Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal CancerNot yet recruitingNCT07154108Lead sponsorPhase 1Start 2025-09
  5. Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06446726Lead sponsorPhase 2Start 2024-06
  6. Neoantigen Vaccines in Esophageal Squamous Cell CarcinomaRecruitingNCT06675201Lead sponsorPhase 2Start 2024-10

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
2.8%Leads about 1 in 36 of China's research papers on HCC

Led 414 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
17
Research papers it led
414
Trials it led
24
Share of China's trials
1.6%
Share of the world's papers
1.4%
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 0020242025: 112025
ThemesRecurrence & prognosisSurgery & liver transplantImaging, AI & early detection

Hospitals counted here

  1. West China Hospital392
  2. Fourth Hospital of Sichuan University Counted in the group total9
  3. West China Second University Hospital Counted in the group total7
  4. West China Hospital of Stomatology Counted in the group total2
  5. West China Health Care Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.2025European journal of medical researchRCTFree full text
  2. Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: a randomized controlled trial.2023International journal of surgery (London, England)RCTFree full text
  3. Tumor burden score-AFP-albumin-bilirubin grade score predicts the survival of patients with hepatocellular carcinoma after liver resection.2023Langenbeck's archives of surgeryRCT
  4. Asia-Pacific multicentre randomized trial of laparoscopic versus open major hepatectomy for hepatocellular carcinoma (AP-LAPO trial).2023BJS openRCTFree full text
  5. A randomized controlled trial of effect of 15- or 25-minute intermittent Pringle maneuver on hepatectomy for hepatocellular carcinoma.2022SurgeryRCT
Trials on ClinicalTrials.gov6
  1. Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.Not yet recruitingNCT07912853Lead sponsorStart 2027-01
  2. YMN-A02 for Advanced Primary Hepatocellular Carcinoma.Not yet recruitingNCT07580261Lead sponsorPhase 1Start 2026-07
  3. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular CarcinomaNot yet recruitingNCT07866612Lead sponsorN/AStart 2026-12
  4. A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular CarcinomaRecruitingNCT07482059Lead sponsorPhase 1/Phase 2Start 2026-02
  5. NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCCRecruitingNCT07295262Lead sponsorEarly phase 1Start 2026-01
  6. Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular CarcinomaRecruitingNCT07410715Lead sponsorStart 2026-03

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.8%Leads about 1 in 55 of China's research papers on Stomach cancer

Led 179 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
5
Research papers it led
179
Trials it led
22
Share of China's trials
1.5%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025
ThemesSurgeryEarly detection & endoscopyImaging & AI

Hospitals counted here

  1. West China Hospital168
  2. West China Hospital of Stomatology Counted in the group total4
  3. West China Second University Hospital Counted in the group total3
  4. Fourth Hospital of Sichuan University Counted in the group total2
  5. fourth Hospital of Sichuan University1
  6. West China Tianfu Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effects of a Comprehensive Program on Reducing Cancer-Related Fatigue: A Randomized Controlled Trial.2025Journal of pain and symptom managementRCT
  2. Combination of dexamethasone and dexmedetomidine as adjuvants of transversus abdominis plane block for postoperative analgesia in gastric cancer patients: A double-blinded randomized controlled trial.2024Journal of clinical anesthesiaRCT
  3. Comparison of long-term quality of life between Billroth-I and Roux-en-Y anastomosis after distal gastrectomy for gastric cancer: a randomized controlled trial.2023Chinese medical journalRCTFree full text
  4. Effects of EN combined with PN enriched with n-3 polyunsaturated fatty acids on immune related indicators and early rehabilitation of patients with gastric cancer: A randomized controlled trial.2022Clinical nutrition (Edinburgh, Scotland)RCT
  5. Effects of Preoperative Oral Nutritional Supplements on Improving Postoperative Early Enteral Feeding Intolerance and Short-Term Prognosis for Gastric Cancer: A Prospective, Single-Center, Single-Blind, Randomized Contro2022NutrientsRCTFree full text
Trials on ClinicalTrials.gov6
  1. Non-surgical Management After NIT for dMMR/MSI-H GCEnrolling by invitationNCT07646574Lead sponsorStart 2026-07
  2. Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ AdenocarcinomaNot yet recruitingNCT07374250Lead sponsorPhase 2Start 2026-02
  3. Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.Not yet recruitingNCT07655661Lead sponsorPhase 2Start 2026-07
  4. XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJCRecruitingNCT06742411Lead sponsorPhase 1/Phase 2Start 2024-12
  5. Personalized DC Vaccine for Postoperative CancerRecruitingNCT04147078Lead sponsorPhase 1Start 2019-06
  6. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
3.2%Leads about 1 in 31 of China's research papers on Hepatoblastoma ▲ from 1.2%

Led 5 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
1
Share of China's trials
10.0%
Share of the world's papers
1.1%
Papers led per year
2021: 1120212022: 0020222023: 3320232024: 0020242025: 002025

Hospitals counted here

  1. West China Hospital4
  2. West China Second University Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Chordoma

脊索瘤
2.9%Leads about 1 in 35 of China's research papers on Chordoma ▲ from 0.8%

Led 3 of 105 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. West China Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
2.1%Leads about 1 in 47 of China's research papers on Osteosarcoma ▲ from 1.2%

Led 48 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
48
Trials it led
1
Share of China's trials
1.7%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. West China Hospital36
  2. West China Hospital of Stomatology5
  3. West China Second University Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
6.3%Leads about 1 in 16 of China's research papers on Gastrointestinal stromal tumour

Led 33 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
33
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025

Hospitals counted here

  1. West China Hospital33
  2. West China Second University Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Development and validation of CT-based nomograms for predicting recurrence and prognosis in gastrointestinal stromal tumor.2026Abdominal radiology (New York)
  2. NF1 Mutated Gastrointestinal Stromal Tumors With Coamplification of MDM2 and MYC.2025Genes, chromosomes & cancer
  3. The feasibility and safety of laparoscopic limited resection for duodenal gastrointestinal stromal tumor: a propensity score-matched analysis.2025Surgical endoscopy
  4. Prognostic factors for metastatic gastrointestinal stromal tumors treated with cytoreductive surgery: a retrospective cohort study.2025Scandinavian journal of gastroenterology
  5. Clinicopathological analysis of anti-VEGF drug-associated renal thrombotic microangiopathy: A case series and review of the literature.2025Pathology, research and practice
Trials on ClinicalTrials.gov6
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)RecruitingNCT04924075Study sitePhase 2Start 2021-08
  3. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Study sitePhase 2Start 2020-04
  4. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  5. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03
  6. A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTStatus unknownNCT02776878Study siteN/AStart 2016-05

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.9%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 10 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
2
Research papers it led
10
Trials it led
3
Share of China's trials
7.1%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. West China Hospital5
  2. West China Second University Hospital3
  3. Fourth Hospital of Sichuan University1
  4. West China Hospital of Stomatology1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Ewing sarcoma

尤文肉瘤
6.1%Leads about 1 in 16 of China's research papers on Ewing sarcoma ▲ from 1.2%

Led 10 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.6%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 112025

Hospitals counted here

  1. West China Hospital9
  2. West China Second University Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
3.8%Leads about 1 in 27 of China's research papers on Myeloma ▲ from 1.4%

Led 63 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
63
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025
ThemesDrug combinationsDiagnosis, MRD & riskRelapse & resistance

Hospitals counted here

  1. West China Hospital59
  2. West China Second University Hospital Counted in the group total2
  3. West China Hospital of Stomatology Counted in the group total1
  4. Fourth Hospital of Sichuan University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Impact of integrated nursing care on rehabilitation process of inpatients with multiple myeloma in an academic hematology department.2025MedicineRCTFree full text
  2. Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma.2023Cancer medicineRCTFree full text
  3. Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.2025Signal transduction and targeted therapyFree full text
  4. Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma.2024Signal transduction and targeted therapyFree full text
  5. Incidence, Clinical Features, and Prognostic Value of New-Onset Renal Impairment in Multiple Myeloma.2025Cancer medicineFree full text
Trials on ClinicalTrials.gov6
  1. A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic MalignanciesRecruitingNCT07255898Study sitePhase 1Start 2026-03
  2. A Clinical Study of TQB2029 for Injection in Subjects With Multiple MyelomaRecruitingNCT06700395Study sitePhase 1Start 2024-11
  3. A Clinical Study of SHR-9539 in Patients With Multiple MyelomaRecruitingNCT06484777Study sitePhase 1Start 2024-08
  4. Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06484829Study sitePhase 1/Phase 2Start 2024-03
  5. A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Study sitePhase 4Start 2022-03
  6. CXCR4 Modified Anti-BCMA CAR T Cells for Multiple MyelomaStatus unknownNCT04727008Lead sponsorPhase 1Start 2022-09

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
1.3%Leads about 1 in 75 of China's research papers on B-ALL ▼ from 2.0%

Led 3 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
1
Share of China's trials
0.4%
Share of the world's papers
0.3%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025
ThemesChildrenAntibody & targeted drugsPhiladelphia chromosome & genetics

Hospitals counted here

  1. West China Second University Hospital2
  2. West China Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
1.7%Leads about 1 in 59 of China's research papers on Aplastic anaemia ▲ from 0.8%

Led 7 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025
ThemesClonal evolution & PNHStem cell transplantImmunosuppressive treatment

Hospitals counted here

  1. West China Hospital4
  2. West China Second University Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
5.0%Leads about 1 in 20 of China's research papers on HLH

Led 20 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
20
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesDiagnosis & prognosisChildrenEBV & infection triggers

Hospitals counted here

  1. West China Hospital12
  2. West China Second University Hospital7
  3. Fourth Hospital of Sichuan University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Beta thalassaemia

β 地中海贫血
1.3%Leads about 1 in 78 of China's research papers on Beta thalassaemia

Led 4 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.9%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 3320222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. West China Second University Hospital2
  2. West China Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
2.2%Leads about 1 in 45 of China's research papers on Haemophilia A

Led 6 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. West China Hospital4
  2. West China Second University Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
3.1%Leads about 1 in 32 of China's research papers on Thrombotic thrombocytopenic purpura New since 2021

Led 2 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. West China Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Thrombotic thrombocytopenic purpura in a patient on long-term alpha-interferon therapy for essential thrombocythemia: a case report.2023BMC nephrology
  2. Therapeutic plasma exchange-free treatment for first-episode TTP: A systematic review.2023Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
7.4%Leads about 1 in 13 of China's research papers on NMOSD

Led 36 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
36
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.9%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 332025
ThemesAntibodies & diagnosisImagingOptic nerve & vision

Hospitals counted here

  1. West China Hospital36

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
4.9%Leads about 1 in 20 of China's research papers on IgG4-RD

Led 12 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesHead, eye socket & salivary glandsTreatment & relapseDiagnosis & look-alikes

Hospitals counted here

  1. West China Hospital11
  2. West China Hospital of Stomatology1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
3.4%Leads about 1 in 29 of China's research papers on Myasthenia gravis

Led 17 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
1
Share of China's trials
1.1%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 552025
ThemesThymus & thymectomyBiologic & complement drugsAntibodies & diagnosis

Hospitals counted here

  1. West China Hospital16
  2. Lung Cancer Medical Center1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A case of immune-related adverse events, thyroid dysfunction, myocarditis with myositis, and myasthenia gravis overlap syndrome following serplulimab administration for lung adenocarcinoma.2025Immunotherapy
  2. The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.2025Neurocritical care
  3. The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis.2025European journal of medical researchFree full text
  4. Impact of body mass index on clinical presentation and prognosis in myasthenia gravis.2025Orphanet journal of rare diseasesFree full text
  5. Clinical study of thyroid eye disease combined with myasthenia gravis.2025Japanese journal of ophthalmology
Trials on ClinicalTrials.gov6
  1. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  2. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Study sitePhase 3Start 2024-06
  3. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia GravisRecruitingNCT05067348Study sitePhase 2Start 2022-07
  4. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  5. A Single-Center, Randomized, Open-Label, Two-Sequence, Two-Period, Crossover Study Comparing the Pharmacokinetics and Safety of Pyridostigmine Sustained-Release and Immediate-Release Tablets Following Single and Multiple Doses in Healthy Chinese ParticipantsCompletedNCT07154095Lead sponsorPhase 1Start 2023-08
  6. Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia GravisStatus unknownNCT05716035Study sitePhase 2/Phase 3Start 2023-04

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
3.1%Leads about 1 in 32 of China's research papers on Moyamoya

Led 11 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025
ThemesImaging & blood flowRevascularisation surgeryStroke & bleeding outcomes

Hospitals counted here

  1. West China Hospital11
  2. West China Second University Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
3.0%Leads about 1 in 33 of China's research papers on Wilson disease

Led 6 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 332025
ThemesGenetics (ATP7B)Diagnosis & copper testsChildren

Hospitals counted here

  1. Fourth Hospital of Sichuan University5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
5.1%Leads about 1 in 19 of China's research papers on Biliary atresia ▲ from 1.5%

Led 11 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
1
Share of China's trials
5.0%
Share of the world's papers
1.5%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 222025
ThemesScreening & diagnosisKasai operationLong-term outcomes

Hospitals counted here

  1. West China Hospital7
  2. West China Second University Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
10.2%Leads about 1 in 10 of China's research papers on Anti-NMDA receptor encephalitis ▼ from 16.9%

Led 27 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
27
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
3.6%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 332025

Hospitals counted here

  1. West China Hospital22
  2. West China Second University Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
2.1%Leads about 1 in 47 of China's research papers on Takayasu arteritis ▼ from 4.4%

Led 4 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. West China Hospital3
  2. West China Second University Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hepatic echinococcosis

肝包虫病
9.2%Leads about 1 in 11 of China's research papers on Hepatic echinococcosis ▼ from 25.0%

Led 14 of 152 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (32.2%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
1
Share of China's trials
50.0%
Share of the world's papers
3.1%
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 1120242025: 002025

Hospitals counted here

  1. West China Hospital14

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
3.4%Leads about 1 in 29 of China's research papers on Idiopathic pulmonary fibrosis ▲ from 1.7%

Led 34 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
34
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. West China Hospital31
  2. West China Second University Hospital2
  3. West China Hospital of Stomatology1
  4. Fourth Hospital of Sichuan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial.2023European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical SciencesRCT
  2. Targeting fibrosis, mechanisms and cilinical trials.2022Signal transduction and targeted therapy
  3. Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosis.2025Respiratory research
  4. Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis.2025PloS one
  5. Acute exacerbation of idiopathic pulmonary fibrosis disease: a diagnosis model in China.2024European journal of medical research
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  3. Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06230822Study sitePhase 1Start 2024-03
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  5. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Study sitePhase 2Start 2024-08
  6. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09

PubMed searchClinicalTrials.gov

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病
6.7%Leads about 1 in 15 of China's research papers on Lymphangioleiomyomatosis ▲ from 3.9%

Led 3 of 45 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.1%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.2%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. West China Hospital2
  2. West China Second University Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led3
  1. Lymphangioleiomyomatosis and pregnancy: a mini-review.2024Archives of gynecology and obstetrics
  2. Diagnostic performance of VEGF-D for lymphangioleiomyomatosis: a meta-analysis.2022Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  3. Sirolimus in the treatment of kaposiform lymphangiomatosis.2021Orphanet journal of rare diseases

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
8.3%Leads about 1 in 12 of China's research papers on Amyotrophic lateral sclerosis

Led 65 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
65
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 442025

Hospitals counted here

  1. West China Hospital60
  2. Fourth Hospital of Sichuan University2
  3. West China Second University Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
5.5%Leads about 1 in 18 of China's research papers on Spinal muscular atrophy New since 2021

Led 3 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

Hospitals counted here

  1. West China Second University Hospital2
  2. West China Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
6.9%Leads about 1 in 15 of China's research papers on Fabry disease ▲ from 4.5%

Led 5 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 332025

Hospitals counted here

  1. West China Hospital5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Pompe disease

庞贝病
6.7%Leads about 1 in 15 of China's research papers on Pompe disease

Led 2 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.7%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

Hospitals counted here

  1. West China Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
10.8%Leads about 1 in 9 of China's research papers on Duchenne muscular dystrophy ▲ from 2.0%

Led 23 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
23
Trials it led
2
Share of China's trials
10.0%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

Hospitals counted here

  1. West China Second University Hospital21
  2. West China Hospital2
  3. Fourth Hospital of Sichuan University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Quantitative Magnetic Resonance Imaging of Gluteal Muscle Groups Detects Stage-Specific Progression and Early-Stage Damage in Duchenne Muscular Dystrophy: A 12-Month Longitudinal Study.2026Muscle & nerve
  2. Phase angle as a predictor of motor function decline in children with Duchenne muscular dystrophy.2025BMC pediatrics
  3. Height development and multiple bone health indicators in children aged 2-12 years with Duchenne muscular dystrophy (DMD).2025PloS one
  4. Association Between Myocardial Oxygenation and Fibrosis in Duchenne Muscular Dystrophy: Analysis by Rest Oxygenation-Sensitive Magnetic Resonance Imaging.2024Journal of magnetic resonance imaging : JMRI
  5. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.2024Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
Trials on ClinicalTrials.gov4
  1. A Multicenter Cohort Study of Duchenne and Becker Muscular Dystrophy in Western Chinese ChildrenNot yet recruitingNCT07511920Lead sponsorStart 2026-04
  2. A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)Active, not recruitingNCT06114056Lead sponsorPhase 1Start 2024-01
  3. Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMDTerminatedNCT04632940Study sitePhase 3Start 2021-03
  4. Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)TerminatedNCT04371666Study sitePhase 3Start 2020-08

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
2.5%Leads about 1 in 41 of China's research papers on Behçet disease ▼ from 3.6%

Led 6 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 2220242025: 112025

Hospitals counted here

  1. West China Hospital6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Alport syndrome

Alport 综合征
5.2%Leads about 1 in 19 of China's research papers on Alport syndrome ▲ from 2.8%

Led 3 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. West China Hospital2
  2. West China Second University Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
5.2%Leads about 1 in 19 of China's research papers on IgA nephropathy ▲ from 4.0%

Led 38 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
38
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
2.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025

Hospitals counted here

  1. West China Hospital34
  2. Chengdu Second People's Hospital1
  3. West China Hospital of Stomatology1
  4. West China Second University Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteogenesis imperfecta

成骨不全症
2.0%Leads about 1 in 50 of China's research papers on Osteogenesis imperfecta

Led 2 of 99 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. West China Second University Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
4.0%Leads about 1 in 25 of China's research papers on Primary biliary cholangitis ▼ from 6.0%

Led 12 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
8
Share of China's trials
16.0%
Share of the world's papers
1.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 3320242025: 112025

Hospitals counted here

  1. West China Hospital11
  2. Gastrointestinal Cancer Centre1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Ursodeoxycholic Acid at 18-22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis.2021Canadian journal of gastroenterology & hepatologyRCT
  2. Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.2024Journal of hepatology
  3. Association of sarcopenia assessed by CT/MRI with treatment response and clinical outcomes in noncirrhotic primary biliary cholangitis patients.2025European journal of radiology
  4. Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis.2024Alimentary pharmacology & therapeutics
  5. Noninvasive prediction of insufficient biochemical response after ursodeoxycholic acid treatment in patients with primary biliary cholangitis based on pretreatment nonenhanced MRI.2024European radiology
Trials on ClinicalTrials.gov6
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  3. Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1Status unknownNCT04618575Lead sponsorPhase 4Start 2021-03
  4. A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap SyndromeStatus unknownNCT04933292Lead sponsorPhase 4Start 2021-06
  5. Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard TherapyStatus unknownNCT04376528Lead sponsorPhase 4Start 2021-06
  6. Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features IIStatus unknownNCT04617561Lead sponsorPhase 4Start 2020-11

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
3.0%Leads about 1 in 33 of China's research papers on Primary sclerosing cholangitis ▼ from 4.1%

Led 3 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
1
Share of China's trials
16.7%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. West China Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Congenital diaphragmatic hernia

先天性膈疝
13.3%Leads about 1 in 8 of China's research papers on Congenital diaphragmatic hernia ▲ from 9.7%

Led 8 of 60 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (18.3%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 222025

Hospitals counted here

  1. West China Hospital5
  2. West China Second University Hospital3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
1.2%Leads about 1 in 81 of China's research papers on Hirschsprung disease ▲ from 0.7%

Led 2 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. West China Second University Hospital1
  2. West China Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症
7.1%Leads about 1 in 14 of China's research papers on Inherited epidermolysis bullosa New since 2021

Led 4 of 56 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.5%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 1120242025: 002025

Hospitals counted here

  1. West China Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hereditary angioedema

遗传性血管性水肿
6.2%Leads about 1 in 16 of China's research papers on Hereditary angioedema New since 2021

Led 2 of 32 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. West China Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov